Literature DB >> 27079315

"Next-generation" mesenchymal stem or stromal cells for the in vivo delivery of bioactive factors: progressing toward the clinic.

Jan A Nolta1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27079315      PMCID： PMC6526951          DOI： 10.1111/trf.13564

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  9 in total

Review 1.  Stem Cell Therapies in Clinical Trials: Progress and Challenges.

Authors:  Alan Trounson; Courtney McDonald
Journal:  Cell Stem Cell       Date:  2015-07-02       Impact factor: 24.633

2.  Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo.

Authors:  Julie Beegle; Kinga Lakatos; Stefanos Kalomoiris; Heather Stewart; R Rivkah Isseroff; Jan A Nolta; Fernando A Fierro
Journal:  Stem Cells       Date:  2015-05-11       Impact factor: 6.277

3.  MSC-based product characterization for clinical trials: an FDA perspective.

Authors:  Michael Mendicino; Alexander M Bailey; Keith Wonnacott; Raj K Puri; Steven R Bauer
Journal:  Cell Stem Cell       Date:  2014-02-06       Impact factor: 24.633

4.  shRNA-mediated decreases in c-Met levels affect the differentiation potential of human mesenchymal stem cells and reduce their capacity for tissue repair.

Authors:  Ivana Rosová; Daniel Link; Jan A Nolta
Journal:  Tissue Eng Part A       Date:  2010-08       Impact factor: 3.845

5.  Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy.

Authors:  Fernando A Fierro; Stefanos Kalomoiris; Claus S Sondergaard; Jan A Nolta
Journal:  Stem Cells       Date:  2011-11       Impact factor: 6.277

6.  Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity.

Authors:  Benjamin J Capoccia; Debra L Robson; Krysta D Levac; Dustin J Maxwell; Sarah A Hohm; Marian J Neelamkavil; Gillian I Bell; Anargyros Xenocostas; Daniel C Link; David Piwnica-Worms; Jan A Nolta; David A Hess
Journal:  Blood       Date:  2009-03-26       Impact factor: 22.113

7.  Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.

Authors:  Ivana Rosová; Mo Dao; Ben Capoccia; Daniel Link; Jan A Nolta
Journal:  Stem Cells       Date:  2008-05-29       Impact factor: 6.277

8.  In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.

Authors:  Gerhard Bauer; Mo A Dao; Scott S Case; Todd Meyerrose; Louisa Wirthlin; Ping Zhou; Xiuli Wang; Phillip Herrbrich; Jesusa Arevalo; Susie Csik; Dianne C Skelton; Jon Walker; Karen Pepper; Donald B Kohn; Jan A Nolta
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

Review 9.  Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia.

Authors:  Aaron Liew; Timothy O'Brien
Journal:  Stem Cell Res Ther       Date:  2012-07-30       Impact factor: 6.832
  9 in total
  3 in total

Review 1.  Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.

Authors:  Milena B P Soares; Renata G J Gonçalves; Juliana F Vasques; Almir J da Silva-Junior; Fernanda Gubert; Girlaine Café Santos; Thaís Alves de Santana; Gabriela Louise Almeida Sampaio; Daniela Nascimento Silva; Massimo Dominici; Rosalia Mendez-Otero
Journal:  Front Mol Neurosci       Date:  2022-06-16       Impact factor: 6.261

2.  Granulocyte-Colony Stimulating Factor-Overexpressing Mesenchymal Stem Cells Exhibit Enhanced Immunomodulatory Actions Through the Recruitment of Suppressor Cells in Experimental Chagas Disease Cardiomyopathy.

Authors:  Daniela N Silva; Bruno S F Souza; Juliana F Vasconcelos; Carine M Azevedo; Clarissa X R Valim; Bruno D Paredes; Vinicius P C Rocha; Gisele B Carvalho; Pamela S Daltro; Simone G Macambira; Carolina K V Nonaka; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

3.  IGF-1-Overexpressing Mesenchymal Stem/Stromal Cells Promote Immunomodulatory and Proregenerative Effects in Chronic Experimental Chagas Disease.

Authors:  Daniela N Silva; Bruno S F Souza; Carine M Azevedo; Juliana F Vasconcelos; Paloma G de Jesus; Malena S Feitoza; Cassio S Meira; Gisele B Carvalho; Bruno Raphael Cavalcante; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Stem Cells Int       Date:  2018-07-24       Impact factor: 5.443
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.